Friends and Foes in Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is a disabling neurodegenerative disease. The prognosis is poor and currently there are no proven effective therapies. Most likely, the etiology is related to cerebral inflammatory processes that cause neuronal damage, resulting in dysfunction and apoptosis of nerve cells. Pathogens that evoke a neuroinflammatory response, collectively activate astrocytes and microglia, which contributes to the secretion of pro-inflammatory cytokines. This leads to the deposit of clustered fragments of beta-amyloid and misfolded tau proteins which do not elicit an adequate immune reaction. Apart from the function of astrocytes and microglia, molecular entities such as TREM2, SYK, C22 and C33 play a role in the physiopathology of AD. Furthermore, bacteria and viruses may trigger an overactive inflammatory response in the brain. Pathogens like Heliobacter pylori, Chlamydia pneumonia and Porphyromonas gingivalis (known for low-grade infection in the oral cavity) can release gingipains, which are enzymes that can damage and destroy neurons. Chronic infection with Borrelia burgdorferi (the causative agent of Lyme disease) can co-localize with tau-tangles and amyloid deposits. As for viral infections, HSV1, cytomegalovirus and Epstein-Barr virus can play a role in the pathogenesis of AD. Present investigations have resulted in the development of antibodies that can clear the brain of beta-amyloid plaques. Trials with humanized aducanumab, lecanomab and donanemab revealed limited success in AD patients. However, AD should be considered as a continuum in which the initial preclinical phase may take 10 or even 20 years. It is generally thought that this phase offers a window for efficacious treatment. Therefore, research is also focused on the identification of biomarkers for early AD detection. In this respect, the plasma measurement of neurofilament light chain in patients treated with hydromethylthionine mesylate may well open a new way to prevent the formation of tau tangles and represents the first treatment for AD at its roots.

Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review

“…Theoretically, targeting tau is expected to have a greater impact on cognitive impairment than targeting antiamyloid proteins [ 82 ]. In addition, other antitau therapies, such as hydromethylthionine mesylate (HMTM), have shown sustained cognitive improvement in AD [ 83 ]. In preclinical testing, salsalate, which prevents tau from being acetylated at Lys174, resulted in reduced p300 HAT activity, which, in turn, led to a decrease in tau acetylation [ 82 ].…”